Venetolax with Azacitidine Drains Fuel from AML Stem Cells

In Nature Medicine, Pollyea et al. (2018) Pollyea D.A. Stevens B.M. Jones C.L. Winters A. Pei S. Minhajuddin M. D’Alessandro A. Culp-Hill R. Riemondy K.A. Gillen A.E. et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 2018; 24 : 1859-1866 Crossref PubMed Scopus (2) Google Scholar recently reported a remarkable overall response of newly diagnosed elderly acute myeloid leukemia patients to a venetoclax and azacitidine combination in a new clinical trial. This treatment reduced succinate dehydrogenase glutathionylation, impaired the tricarboxylic acid cycle, and depleted ATP in leukemia stem cells